Nature Medicine:

LRI President Margaret Dowd says FDA’s recent approval of Benlysta™ gives industry the confidence to move forward on other lupus therapies.

Benlysta, a human monoclonal antibody drug, is now approved by the US Food and Drug Administration to treat systemic lupus erythematosus, a painful autoimmune disorder that can damage the joints, heart, kidneys and lungs.

Read full story (PDF)